Commit and Gastroesophageal reflux disease - a phase IV clinical study of FDA data

Summary:

Gastroesophageal reflux disease is found among people who take Commit, especially for people who are male, 50-59 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Commit and have Gastroesophageal reflux disease. It is created by eHealthMe based on reports of 4,830 people who have side effects when taking Commit from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 24, 2023

4,830 people reported to have side effects when taking Commit.
Among them, 17 people (0.35%) have Gastroesophageal reflux disease.

What is Commit?

Commit has active ingredients of nicotine polacrilex. eHealthMe is studying from 4,836 Commit users for its effectiveness, alternative drugs and more.

What is Gastroesophageal reflux disease?

Gastroesophageal reflux disease (a condition in which stomach contents leak backward from the stomach into the oesophagus) is found to be associated with 3,743 drugs and 3,310 conditions by eHealthMe.

Number of Commit and Gastroesophageal reflux disease reports submitted per year:

Could Commit cause Gastroesophageal reflux disease?

Time on Commit when people have Gastroesophageal reflux disease *:

Gender of people who have Gastroesophageal reflux disease when taking Commit *:

female: 50 %
male: 50 %

Age of people who have Gastroesophageal reflux disease when taking Commit *:

Common drugs people take besides Commit *:

Nicorette: 2 people, 11.76%
Nicotine Polacrilex: 1 person, 5.88%

Common side effects people have besides Gastroesophageal reflux disease *:

Indigestion: 4 people, 23.53%
Nausea (feeling of having an urge to vomit): 3 people, 17.65%
Throat Irritation: 2 people, 11.76%
Malaise (a feeling of general discomfort or uneasiness): 2 people, 11.76%
Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough): 1 person, 5.88%
Abdominal Distension: 1 person, 5.88%
Abdominal Pain: 1 person, 5.88%
Candidiasis (candidiasis or thrush is a fungal infection): 1 person, 5.88%
Chest Pain: 1 person, 5.88%
Dizziness: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Commit and have Gastroesophageal reflux disease?

Check whether Gastroesophageal reflux disease is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Gastroesophageal reflux disease and when was it recovered:

Gastroesophageal reflux disease in Commit

Expand to all the drugs that have ingredients of nicotine polacrilex:

Gastroesophageal reflux disease and drugs with ingredients of nicotine polacrilex (101 reports)

Alternative drugs to, pros and cons of Commit:

Commit (4,836 reports)

Common Commit side effects:

Browse all side effects of Commit:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Gastroesophageal reflux disease treatments and more:

Gastroesophageal reflux disease (399,856 reports)

COVID vaccines that are related to Gastroesophageal reflux disease:

Common drugs associated with Gastroesophageal reflux disease:

All the drugs that are associated with Gastroesophageal reflux disease:

Gastroesophageal reflux disease (3,743 drugs)

Common conditions associated with Gastroesophageal reflux disease:

High blood pressure: 8,283 reports
Osteoporosis: 6,304 reports
Pain: 4,963 reports

All the conditions that are associated with Gastroesophageal reflux disease:

Gastroesophageal reflux disease (3,310 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nicotine polacrilex (the active ingredients of Commit) and Commit (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.